These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 9382366)

  • 1. Association between CCR5 genotype and the clinical course of HIV-1 infection.
    de Roda Husman AM; Koot M; Cornelissen M; Keet IP; Brouwer M; Broersen SM; Bakker M; Roos MT; Prins M; de Wolf F; Coutinho RA; Miedema F; Goudsmit J; Schuitemaker H
    Ann Intern Med; 1997 Nov; 127(10):882-90. PubMed ID: 9382366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1-infected long-term slow progressors heterozygous for delta32-CCR5 show significantly lower plasma viral load than wild-type slow progressors.
    Walli R; Reinhart B; Luckow B; Lederer E; Loch O; Malo A; Wank R; Schlöndorff D; Goebel FD
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Jul; 18(3):229-33. PubMed ID: 9665499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.
    Bratt G; Leandersson AC; Albert J; Sandström E; Wahren B
    AIDS; 1998 May; 12(7):729-36. PubMed ID: 9619804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased frequency of CCR-5 delta 32 heterozygotes among long-term non-progressors with HIV-1 infection. The Australian Long-Term Non-Progressor Study Group.
    Stewart GJ; Ashton LJ; Biti RA; Ffrench RA; Bennetts BH; Newcombe NR; Benson EM; Carr A; Cooper DA; Kaldor JM
    AIDS; 1997 Dec; 11(15):1833-8. PubMed ID: 9412701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CC chemokine receptor 5 cell-surface expression in relation to CC chemokine receptor 5 genotype and the clinical course of HIV-1 infection.
    de Roda Husman AM; Blaak H; Brouwer M; Schuitemaker H
    J Immunol; 1999 Oct; 163(8):4597-603. PubMed ID: 10510404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of heterozygosity for the chemokine receptor CCR5 32-bp-deleted allele on plasma virus load and CD4 T lymphocytes in perinatally human immunodeficiency virus-infected children at 8 years of age.
    Buseyne F; Janvier G; Teglas JP; Ivanoff S; Burgard M; Bui E; Mayaux MJ; Blanche S; Rouzioux C; Rivière Y
    J Infect Dis; 1998 Oct; 178(4):1019-23. PubMed ID: 9806029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective effect of CCR5 delta 32 heterozygosity is restricted by SDF-1 genotype in children with HIV-1 infection.
    Sei S; Boler AM; Nguyen GT; Stewart SK; Yang QE; Edgerly M; Wood LV; Brouwers P; Venzon DJ
    AIDS; 2001 Jul; 15(11):1343-52. PubMed ID: 11504955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infectious cellular load in human immunodeficiency virus type 1 (HIV-1)-infected individuals and susceptibility of peripheral blood mononuclear cells from their exposed partners to non-syncytium-inducing HIV-1 as major determinants for HIV-1 transmission in homosexual couples.
    Blaak H; van't Wout AB; Brouwer M; Cornelissen M; Kootstra NA; Albrecht-van Lent N; Keet RP; Goudsmit J; Coutinho RA; Schuitemaker H
    J Virol; 1998 Jan; 72(1):218-24. PubMed ID: 9420218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterozygosity for a defective gene for CC chemokine receptor 5 is not the sole determinant for the immunologic and virologic phenotype of HIV-infected long-term nonprogressors.
    Cohen OJ; Vaccarezza M; Lam GK; Baird BF; Wildt K; Murphy PM; Zimmerman PA; Nutman TB; Fox CH; Hoover S; Adelsberger J; Baseler M; Arthos J; Davey RT; Dewar RL; Metcalf J; Schwartzentruber DJ; Orenstein JM; Buchbinder S; Saah AJ; Detels R; Phair J; Rinaldo C; Margolick JB; Pantaleo G; Fauci AS
    J Clin Invest; 1997 Sep; 100(6):1581-9. PubMed ID: 9294127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations of CCR5, CCR2, and stromal cell-derived factor 1 genotypes with human immunodeficiency virus disease progression in patients receiving nucleoside therapy.
    Lathey JL; Tierney C; Chang SY; D'Aquila RT; Bettendorf DM; Alexander HC; Santini CD; Hughes AM; Barroga CF; Spector SA; Landes JE; Hammer SM; Katzenstein DA
    J Infect Dis; 2001 Dec; 184(11):1402-11. PubMed ID: 11709782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CCR5/delta(ccr5) heterozygosity: a selective pressure for the syncytium-inducing human immunodeficiency virus type 1 phenotype. NIAID AIDS Clinical Trials Group Protocol 241 Virology Team.
    D'Aquila RT; Sutton L; Savara A; Hughes MD; Johnson VA
    J Infect Dis; 1998 Jun; 177(6):1549-53. PubMed ID: 9607832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early protective effect of CCR-5 delta 32 heterozygosity on HIV-1 disease progression: relationship with viral load. The SEROCO Study Group.
    Meyer L; Magierowska M; Hubert JB; Rouzioux C; Deveau C; Sanson F; Debre P; Delfraissy JF; Theodorou I
    AIDS; 1997 Sep; 11(11):F73-8. PubMed ID: 9302436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of CCR2 genotype in the clinical course of syncytium-inducing (SI) or non-SI human immunodeficiency virus type 1 infection and in the time to conversion to SI virus variants.
    van Rij RP; de Roda Husman AM; Brouwer M; Goudsmit J; Coutinho RA; Schuitemaker H
    J Infect Dis; 1998 Dec; 178(6):1806-11. PubMed ID: 9815240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome.
    Katzenstein TL; Pedersen C; Nielsen C; Lundgren JD; Jakobsen PH; Gerstoft J
    AIDS; 1996 Feb; 10(2):167-73. PubMed ID: 8838704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models.
    Edo-Matas D; Lemey P; Tom JA; Serna-Bolea C; van den Blink AE; van 't Wout AB; Schuitemaker H; Suchard MA
    Mol Biol Evol; 2011 May; 28(5):1605-16. PubMed ID: 21135151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCR5 promoter polymorphisms, CCR5 59029A and CCR5 59353C, are under represented in HIV-1-infected long-term non-progressors. The Australian Long-Term Non-Progressor Study Group.
    Clegg AO; Ashton LJ; Biti RA; Badhwar P; Williamson P; Kaldor JM; Stewart GJ
    AIDS; 2000 Jan; 14(2):103-8. PubMed ID: 10708279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between CCR5
    Martínez-Bonet M; González-Serna A; Clemente MI; Morón-López S; Díaz L; Navarro M; Puertas MC; Leal M; Ruiz-Mateos E; Martinez-Picado J; Muñoz-Fernández MA
    Clin Microbiol Infect; 2017 May; 23(5):318-324. PubMed ID: 28042001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4 T cell surface CCR5 density as a host factor in HIV-1 disease progression.
    Reynes J; Portales P; Segondy M; Baillat V; André P; Avinens O; Picot MC; Clot J; Eliaou JF; Corbeau P
    AIDS; 2001 Sep; 15(13):1627-34. PubMed ID: 11546936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Causal pathways for CCR5 genotype and HIV progression.
    Taylor JM; Wang Y; Ahdieh L; Chmiel JS; Detels R; Giorgi JV; Kaslow R; Kingsley L; Margolick J
    J Acquir Immune Defic Syndr; 2000 Feb; 23(2):160-71. PubMed ID: 10737431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study.
    Yeo AE; Matsumoto A; Hisada M; Shih JW; Alter HJ; Goedert JJ
    Ann Intern Med; 2000 Jun; 132(12):959-63. PubMed ID: 10858179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.